PARP1 expression drives the synergistic antitumor activity of trabectedin and PARP1 inhibitors in sarcoma preclinical models

BACKGROUND: Enhancing the antitumor activity of the DNA-damaging drugs is an attractive strategy to improve current treatment options. Trabectedin is an isoquinoline alkylating agent with a peculiar mechanism of action. It binds to minor groove of DNA inducing single- and double-strand-breaks. These...

Descripción completa

Detalles Bibliográficos
Autores principales: Pignochino, Ymera, Capozzi, Federica, D’Ambrosio, Lorenzo, Dell’Aglio, Carmine, Basiricò, Marco, Canta, Marta, Lorenzato, Annalisa, Vignolo Lutati, Francesca, Aliberti, Sandra, Palesandro, Erica, Boccone, Paola, Galizia, Danilo, Miano, Sara, Chiabotto, Giulia, Napione, Lucia, Gammaitoni, Loretta, Sangiolo, Dario, Benassi, Maria Serena, Pasini, Barbara, Chiorino, Giovanna, Aglietta, Massimo, Grignani, Giovanni
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2017
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5410089/
https://www.ncbi.nlm.nih.gov/pubmed/28454547
http://dx.doi.org/10.1186/s12943-017-0652-5

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5410089/
https://www.ncbi.nlm.nih.gov/pubmed/28454547
http://dx.doi.org/10.1186/s12943-017-0652-5

Ejemplares similares